| Sunday March 14, 1999 - PM | ... |
- Angela McLean - The role of target cell dynamics in treatment failure
| Monday March 15, 1999 - AM | HIV drug resistance and viral fitness |
Brenden Larder, discussion leader
- David Stammers - Structure of HIV-1 RT containing NRTI/NNRTI mutations
- Jaap Goudsmit - Mechanisms ruling RT-dependent HIV-1 fitness in vivo
- Ron Swanstrom - Relative growth rates of HIV - 1 strains with mutant potease
- Brenden Larder - New development in protease and nucleoside analogue resistance
- Gordon Conference 1999 photo
| Monday March 15, 1999 - PM | New antivirals and therapeutic targets |
Daria Hazuda, discussion leader
- Osvaldo Flores - pTEFb and Tat kinase inhibitors
- Daria Hazuda - Integrase inhibitors
- Wesley Sunquist - In vitro virus assembly
| Tuesday March 16, 1999 - AM | Next generation of protease and reverse transcriptase inhibitors |
Norbert Bischofberger, discussion leader
- Amy Patick - Antiviral activity and resistance profiles of a new HIV-1 nonnucleoside reverse transcriptase inhibitor, AG1549 and a new HIV-1 protease inhibitor AG1776
- William Freimuth - Tipranavir: a different protease inhibitor
- Philip Furman - New inhibitors of HIV-1 reverse transcriptase
- Anthony Japour - Safety and virological activity of ABT-378/ritonavir in naive and PI-experienced patients
- Emilio Emini - Characteristics of L-756-423: A new , potent HIV-1 protease inhibitor with Potential for Simplified Dosing
| Tuesday March 16, 1999 - PM | Long term side effects of HAART |
Judith Currier, discussion leader
- Kathy Mulligan - Metabolic complications of HIV
- Donald Kotler - Body composition changes in patients treated with HAART
- Alan Landay - Surrogate Markers of Immune Restoration in Multicenter HIV Therapy Trials
| Wednesday March 17, 1999 - AM | Acute HIV infection and immune responses post HAART |
Martin Markowitz, discussion leader
- Eric Rosenberg - Effects of HAART on HIV specific immune responses
- Douglas Nixon - Impact of antiretroviral therapy on HIV-specific cellular immune responses
- Martin Markowitz - Treatment of primary infection
- Sharon Lewin - Primary HIV-1 infection: Natural history
| Wednesday March 17, 1999 - PM | Inhibitors of HIV binding and entry |
Michael Luther, discussion leader
- Michael Luther - Overview
- Martin Springer - Coreceptor-envelope Interactions: Potential and Requirements for
Therapeutic Intervention
- Robert Doms - Functional analyses of HIV-1 coreceptors and implications for antiretroviral agents
- Joseph Sodroski - Potential targets for intervention on the gp120 envelope glycoprotein
- Dennis Lambert - T-20: A novel HIV therapeutic
| Thursday March 18, 1999 - AM | Clinical trials: challenges for the future |
Anthony Japour, discussion leader
- Anthony Japour - Overview of issues
- William Cameron - Perspectives on Phase III clinical studies
- Robert Yarchaon - Phase I/II studies in the era of HAART
- Jeffrey Murray - Clearing the safety and efficacy hurdle with virologic endpoint studies
| Thursday March 18, 1999 - PM | Reservoirs of HIV: is eradication achievable? |
Robert Siliciano, discussion leader
- David Ho - Eradication of residual HIV replication after seemingly effective suppression by HAART
- Robert Siliciano - Latent reservoirs for HIV: Implications for virus eradication
|
